Vivanza Biosciences Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 515837, "name": "Vivanza Biosci.", "stock_name": "Vivanza Biosci.", "full_name": "Vivanza Biosciences Ltd", "name_url": "stocks-analysis/vivanza-biosci", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "1.74", "chg": -0.01, "chgp": "-0.57%", "dir": -1, "prev_price": "1.75", "mcapval": "7.00 Cr", "mcap": "Micro Cap", "scripcode": 530057, "symbol": "", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 67, "indexname": "India SENSEX", "isin": "INE984E01035", "curr_date": "May 29", "curr_time": "", "bse_nse_vol": "93.77 k", "exc_status": "Active", "traded_date": "May 29, 2026", "traded_date_str": "2026 05 29", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vivanza-biosci-515837-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Vivanza Biosciences Declines 1.69% Amid Mixed Technical Signals and Financial Challenges", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-declines-169-amid-mixed-technical-signals-and-financial-challenges-4023469", "imagepath": "", "date": "2026-05-30 17:06:31", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>25 May:</strong> Stock opens steady at Rs.1.77 with no price change</p>\n <p><strong>26 May:</strong> Rating upgraded to Sell by MarketsMOJO on technical improvements</p>\n <p><strong>27 May:</strong> Stock dips 1.13% to Rs.1.75 amid mixed market signals</p>\n <p><strong>29 May:</strong> New 52-week low of Rs.1.74 recorded, closing the week down 1.69%</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1.77</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div..." }, { "title": "Vivanza Biosciences Ltd Falls to 52-Week Low of Rs 1.74 as Sell-Off Deepens", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-falls-to-52-week-low-of-rs174-amidst-continued-downtrend-4020113", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/VivanzaBioscien_priceRelatedfactors_4020113.png", "date": "2026-05-29 10:41:33", "description": "A sustained decline has pushed Vivanza Biosciences Ltd to a fresh 52-week low of Rs 1.74 on 29 May 2026, marking a 28.4% drop over the past year and signalling continued pressure on this micro-cap pharmaceutical stock despite some recent positive financial results." }, { "title": "Vivanza Biosciences Ltd Upgraded to Sell on Technical Improvements Despite Long-Term Challenges", "link": "https://www.marketsmojo.com/news/stock-recommendation/vivanza-biosciences-ltd-upgraded-to-sell-on-technical-improvements-despite-long-term-challenges-4012939", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/VivanzaBioscien_mojoScore_4012939.png", "date": "2026-05-26 08:34:57", "description": "Vivanza Biosciences Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 25 May 2026, driven primarily by a shift in technical indicators amid persistent fundamental weaknesses. While the company’s financial trend shows some positive quarterly results, its long-term fundamentals and valuation metrics continue to weigh on investor sentiment, resulting in a cautious outlook." }, { "title": "Vivanza Biosciences Downgraded to Strong Sell Amid Technical and Fundamental Weakness", "link": "https://www.marketsmojo.com/news/stock-recommendation/vivanza-biosciences-downgraded-to-strong-sell-amid-technical-and-fundamental-weakness-3998309", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/VivanzaBioscien_mojoScore_3998309.png", "date": "2026-05-19 08:30:38", "description": "Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 18 May 2026. This revision reflects deteriorating technical indicators, persistent operating losses, and weak long-term fundamentals despite recent positive quarterly financial results." }, { "title": "Vivanza Biosciences Falls 5.00%: Valuation Shifts and Q4 Losses Shape the Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-falls-500-valuation-shifts-and-q4-losses-shape-the-week-3983601", "imagepath": "", "date": "2026-05-09 17:05:41", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>May 4:</strong> Week opens at Rs.2.00</p>\n <p><strong>May 6:</strong> Valuation shifts signal changing price attractiveness</p>\n <p><strong>May 8:</strong> Q4 FY26 results reveal sharp loss reversal despite revenue surge</p>\n <p><strong>May 8:</strong> Stock closes week at Rs.1.90 (-5.00%)</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.2.00</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1.90</div><div class=\"stat-change neg..." }, { "title": "Are Vivanza Biosciences Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-vivanza-biosciences-ltd-latest-results-good-or-bad-3982328", "imagepath": "", "date": "2026-05-08 19:18:11", "description": "Vivanza Biosciences Ltd's latest financial results for Q4 FY26 reveal significant operational challenges despite remarkable year-on-year revenue growth. The company reported net sales of ₹6.36 crores, reflecting an extraordinary increase of 1,225.00% compared to the same quarter last year. However, this figure represents a substantial sequential decline of 85.94% from ₹45.25 crores in Q3 FY26, raising concerns about revenue volatility and sustainability.\n\nThe net profit for the quarter was a loss of ₹0.45 crores, marking a 325.00% decline from the previous quarter and a 55.00% decline year-on-year. This loss indicates that the company is currently loss-making on a trailing twelve-month basis, which has led to questions regarding its ability to achieve sustainable profitability.\n\nThe operating profit before depreciation, interest, tax, and other income (PBDIT) turned negative at -₹0.24 crores, resulting in a..." }, { "title": "Vivanza Biosciences Q4 FY26: Sharp Loss Reversal Raises Red Flags Despite Revenue Surge", "link": "https://www.marketsmojo.com/news/result-analysis/vivanza-biosciences-q4-fy26-sharp-loss-reversal-raises-red-flags-despite-revenue-surge-3981988", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/VivanzaBioscien_quaterlyResult_3981988.png", "date": "2026-05-08 14:46:41", "description": "Vivanza Biosciences Ltd., the Gujarat-based pharmaceutical company with a market capitalisation of ₹8.00 crores, reported a troubling quarter-on-quarter deterioration in Q4 FY26, swinging to a net loss of ₹0.45 crores from a profit of ₹0.20 crores in the previous quarter. The 325.00% decline in profitability overshadowed an otherwise impressive year-on-year revenue growth trajectory, raising serious concerns about operational efficiency and cost management at the micro-cap pharmaceutical player." }, { "title": "Vivanza Biosciences Ltd: Valuation Shifts Signal Changing Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/vivanza-biosciences-ltd-valuation-shifts-signal-changing-price-attractiveness-3976696", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/VivanzaBioscien_valuationdot_3976696.png", "date": "2026-05-06 08:00:25", "description": "Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift from attractive to fair, reflecting a nuanced change in price attractiveness despite ongoing operational challenges and a tough market backdrop." }, { "title": "When is the next results date for Vivanza Biosciences Ltd?", "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-vivanza-biosciences-ltd-3976541", "imagepath": "", "date": "2026-05-05 23:16:40", "description": "The next results date for Vivanza Biosciences Ltd is scheduled for 07 May 2026...." } ], "total": 194, "sid": "515837", "stock_news_url": "https://www.marketsmojo.com/news/vivanza-biosciences-515837" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "09-May-2026", "details": "In terms of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Please find enclosed copy of newspaper advertisement published in English daily Newspaper (Indian Express) and one daily newspaper (Financial Express) in Gujarati language of the region where the registered office of the Company is situated for extract of Audited Standalone and Consolidated Financial Results for the Quarter and Financial Year ended on March 31st 2026", "source": "BSE" }, { "caption": "Results- Quarterly And Year To End Dated 31St March 2026", "datetime": "07-May-2026", "details": "Audited Standalone Financial Results for the Quarter and Year ended on 31st March 2026 Took note of resignation of Hemant A. Parikh as an MD and Chaitra Arora a CS Reconstitution of Committees of the Board", "source": "BSE" }, { "caption": "Non Applicability Of Related Party Transaction Under Regulation 23(9) Of SEBI (LODR) Regulations 2015 For The Quarter And Year Ended 31St March 2026", "datetime": "07-May-2026", "details": "This is to inform you that as per Regulation 15(2) of SEBI (LODR) Regulations 2015 Corporate Governance and the above mentioned provisions such as Regulation 23(9) of SEBI (LODR) Regulations 2015 shall not apply to listed entities having paid up equity share capital not exceeding Rupees 10 crores and net worth not exceeding Rupees 25 crores as on the last day of previous financial year. The paid-up equity share capital and net worth of the Company as on 31st March 2025 are Rs. 40000000 and Rs. 40203752.40 respectively", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Vivanza Biosciences Ltd has announced <strong>1:10</strong> stock split, ex-date: 24 Mar 23", "dt": "2023-03-24", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

May 4: Week opens at Rs.2.00

May 6: Valuation shifts signal changing price attractiveness

May 8: Q4 FY26 results reveal sharp loss reversal despite revenue surge

May 8: Stock closes week at Rs.1.90 (-5.00%)

Read full news article

Are Vivanza Biosciences Ltd latest results good or bad?

2026-05-08 19:18:11

Vivanza Biosciences Ltd's latest financial results for Q4 FY26 reveal significant operational challenges despite remarkable year-on-year revenue growth. The company reported net sales of ₹6.36 crores, reflecting an extraordinary increase of 1,225.00% compared to the same quarter last year. However, this figure represents a substantial sequential decline of 85.94% from ₹45.25 crores in Q3 FY26, raising concerns about revenue volatility and sustainability. The net profit for the quarter was a loss of ₹0.45 crores, marking a 325.00% decline from the previous quarter and a 55.00% decline year-on-year. This loss indicates that the company is currently loss-making on a trailing twelve-month basis, which has led to questions regarding its ability to achieve sustainable profitability. The operating profit before depreciation, interest, tax, and other income (PBDIT) turned negative at -₹0.24 crores, resulting in a...

Read full news article

Vivanza Biosciences Q4 FY26: Sharp Loss Reversal Raises Red Flags Despite Revenue Surge

2026-05-08 14:46:41

Vivanza Biosciences Ltd., the Gujarat-based pharmaceutical company with a market capitalisation of ₹8.00 crores, reported a troubling quarter-on-quarter deterioration in Q4 FY26, swinging to a net loss of ₹0.45 crores from a profit of ₹0.20 crores in the previous quarter. The 325.00% decline in profitability overshadowed an otherwise impressive year-on-year revenue growth trajectory, raising serious concerns about operational efficiency and cost management at the micro-cap pharmaceutical player.

Read full news article

Vivanza Biosciences Ltd: Valuation Shifts Signal Changing Price Attractiveness

2026-05-06 08:00:25

Vivanza Biosciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift from attractive to fair, reflecting a nuanced change in price attractiveness despite ongoing operational challenges and a tough market backdrop.

Read full news article

When is the next results date for Vivanza Biosciences Ltd?

2026-05-05 23:16:40

The next results date for Vivanza Biosciences Ltd is scheduled for 07 May 2026....

Read full news article